课题基金 / 基金详情

Deciphering the Implementability of Epigenetic Reprogramming in Hematopoietic Stem Cells as a Novel Vaccination Strategy against Human Tuberculosis

Deciphering the Implementability of Epigenetic Reprogramming in Hematopoietic Stem Cells as a Novel Vaccination Strategy against Human Tuberculosis
破译造血干细胞表观遗传重编程作为人类结核病新型疫苗接种策略的可行性
批准号：
413227
负责人：
Kaufmann Eva
金额：
$9.83万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-10-01 至 2022-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=413227&lang=en
关键词：
Bcg Hematopoietic Stem Cells Humanized Mice Innate Immune System Mouse Models Mycobacterium Tuberculosis Trained Immunity Tuberculosis Vaccination

项目摘要

项目成果

Kaufmann Eva的其他基金

相似基金

相关文献

中文摘要
翻译
自从德国科学家罗伯特·科赫（Robert Koch）在1882年发现结核分枝杆菌（Mtb）是结核病的传染因子以来，科学家们一直在努力预防或治愈这种疾病。古埃及母亲中Mtb DNA的存在
英文摘要
Ever since the German scientist Robert Koch discovered Mycobacterium tuberculosis (Mtb) to be the infectious agent of tuberculosis in 1882, it has defied efforts by scientists to prevent or cure the disease. The presence of Mtb DNA in ancient Egyptian mum
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chairs - Tier 2
海外基金